EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.

Anna-Dorothea Wagner,Yoon-Koo Kang,Jolanda van Dieren,Murielle Mauer,Heike I. Grabsch,Michela Lia,Ajlan Atasoy,Jae Yong Cho,Markus Moehler,Arnaud Roth,Manuel Salto-Tellez,Christoph Schumacher,Nicole C.T. van Grieken,Johanna W. van Sandick,Florian Lordick

EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.

2016

Anna-Dorothea Wagner
Yoon-Koo Kang
Jolanda van Dieren
Murielle Mauer
Heike I. Grabsch
Michela Lia
Ajlan Atasoy
Jae Yong Cho
Markus Moehler
Arnaud Roth
Manuel Salto-Tellez
Christoph Schumacher
Nicole C.T. van Grieken
Johanna W. van Sandick
Florian Lordick

TPS4133Background: Approximately 10-20% of patients with gastric cancer (GCa) have HER-2 positive tumors. The addition of T to cisplatin/fluoropyrimidine-based CT improved survival in metastatic HE...

Keywords:

Stomach cancer
Trastuzumab
General surgery
Pertuzumab
Physical therapy
Perioperative
Chemotherapy
Medicine
perioperative chemotherapy
improved survival
Oncology
Cancer
Internal medicine
Cisplatin
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations